First (18)F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts

Research output: Contribution to journalJournal articlepeer-review

Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.
Original languageEnglish
JournalNuclear Medicine and Biology
Volume40
Issue number5
Pages (from-to)618-24
Number of pages7
ISSN0969-8051
DOIs
Publication statusPublished - Jul 2013

ID: 45945354